Advertisement
Screener

Allarity Therapeutics, Inc. (ALLR) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

0.8 / 5 stars · 3/18 Roast Me

Allarity Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

Allarity Therapeutics, Inc. (ALLR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 25.00 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.

Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-03-30

  • Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
  • Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 0.00 shares.
  • Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-12-31 was 7.00 shares.
  • Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-09-30 was -6.00 shares, a 154.55% decline year-over-year.
  • Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 25.00K shares, a 277677.78% increase from fiscal 2024.
  • Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 9.00 shares, a 800.00% increase from fiscal 2023.
  • Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.00 shares, a 100.00% decline from fiscal 2022.
  • Allarity Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 544.04K shares, a 1087.73% increase from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month as first filedShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed
2025-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
0.00 shares
derived: sum of 2 quarters · filed 2026-03-30
25.00K shares
10-K · filed 2026-03-30
2025-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
25.00K shares
10-Q · filed 2025-11-14
2025-06-3025.00K shares
10-Q · filed 2025-08-15
2024-12-317.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
1.00 shares
derived: sum of 2 quarters · filed 2026-03-30
4.00 shares
derived: sum of 3 quarters · filed 2026-03-30
9.00 shares
10-K · filed 2026-03-30
2024-09-30-6.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
-3.00 shares
derived: sum of 2 quarters · filed 2024-11-14
2.00 shares
10-Q · filed 2024-11-14
-79.00 shares
derived: sum of 4 quarters · filed 2025-03-31
2024-06-303.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05
8.00 shares
10-Q · filed 2024-08-05
-73.00 shares
derived: sum of 3 quarters · filed 2025-03-31
-62.00 shares
derived: sum of 4 quarters · filed 2025-03-31
2024-03-315.00 shares
10-Q · filed 2024-05-14
-76.00 shares
derived: sum of 2 quarters · filed 2025-03-31
-65.00 shares
derived: sum of 3 quarters · filed 2025-03-31
-1.76K shares
derived: sum of 4 quarters · filed 2025-03-31
2023-12-31-81.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
-70.00 shares
derived: sum of 2 quarters · filed 2025-03-31
-1.76K shares
derived: sum of 3 quarters · filed 2025-03-31
1.00 shares
10-K · filed 2025-03-31
101.00 shares
10-K · filed 2024-03-08
2023-09-3011.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
-1.68K shares
derived: sum of 2 quarters · filed 2023-11-14
82.00 shares
10-Q · filed 2023-11-14
82.00 shares
derived: sum of 4 quarters · filed 2023-11-14
2023-06-30-1.69K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
71.00 shares
10-Q · filed 2023-08-14
71.00 shares
derived: sum of 3 quarters · filed 2023-08-14
2023-03-311.76K shares
10-Q · filed 2023-05-11
1.76K shares
derived: sum of 2 quarters · filed 2023-05-11
2022-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13
544.04K shares
10-K · filed 2023-03-13
2022-09-30544.04K shares
10-Q · filed 2022-11-14
2021-12-3145.80K shares
10-K · filed 2022-05-17
2021-09-3040.60K shares
10-Q/A · filed 2022-05-17
2.03M shares
10-Q · filed 2021-11-23
2020-12-3127.02K shares
10-Q/A · filed 2022-05-17
1.35M shares
10-Q · filed 2021-11-23
27.02K shares
10-K · filed 2022-05-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Lipocine Inc. (LPCN)United States$0.017B-1.79
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Korsana Biosciences, Inc. (CYCN)United States$0.016B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
Rocket One Inc. (RKTO)United States$0.019B
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B